Pleco Therapeutics Announces Final Close of its Series A Financing Raising €17.3m to Progress its Novel Plecoid™ Product in Acute Myeloid Leukaemia to Regulatory Filing in USA and EU

/PRNewswire/ -- Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel treatments designed to detoxify the cancer micro-environment...

Related Keywords

Netherlands ,Nijmegen ,Gelderland ,New Jersey ,United States ,Newark ,Michael Stalhamer ,Ivo Timmermans ,Ondernemend Nederland ,Sue Charles ,Hyloris Pharmaceuticals Sa Euronext Brussels ,Linkedin ,Twitter ,Netherlands Enterprise Agency Rijksdienst ,Regulatory Affairs ,Vp Product Development ,Pleco Therapeutics United States Inc ,Acute Myeloid Leukaemia ,Netherlands Enterprise Agency ,Hyloris Pharmaceuticals ,Euronext Brussels ,Small Cell Lung Cancer ,Chief Executive Officer ,Pleco Therapeutics ,Innovation Credit ,Pleco Therapeutics United States ,Vice President ,Product Development ,Stat Facts ,Acute Myeloid Leukemia ,Charles Consultants ,